Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications

Children account for 7%–20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneou...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Pediatric Infectious Diseases Society 2015-12, Vol.4 (4), p.356-358
Main Authors: Layegh, Pouran, Khademi, Zeinab, Afzal Aghaee, Monavar, Moghiman, Toktam
Format: Article
Language:English
Subjects:
Adolescent
Antiprotozoal Agents - adverse effects
Antiprotozoal Agents - therapeutic use
Child
Child, Preschool
Female
Humans
Infant
Iran
Leishmaniasis, Cutaneous - drug therapy
Male
Meglumine - adverse effects
Meglumine - therapeutic use
Organometallic Compounds - adverse effects
Organometallic Compounds - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Children account for 7%–20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneous leishmaniasis. Adverse effects were similar to those seen in adults.
ISSN:2048-7193
2048-7207
DOI:10.1093/jpids/piu021